Healthcare Startups for the Tech Savvy
10:45 AM – 11:45 AM, Ferman Conference Room
Finding opportunities in the healthcare arena

MODERATOR
Edward Chwieseni, President and CEO, PracticeForces
Edward Chwieseni is the Director of IT for Moffitt Cancer Center and its wholly owned subsidiary M2Gen. He is responsible for IT strategy, planning and implementation efforts at Moffitt and M2Gen, including software development, data warehousing, project management, clinical trials systems, research IT projects and IT infrastructure and has over 28 years of experience working in IT. Before joining the Moffitt group, Mr. Chwieseni held multiple senior (CIO, CTO, and CTIO) positions at a number of early stage companies. Mr. Chwieseni has a BS (Hons) Computer Science from Teesside, an MBA from Phoenix, and is currently working on his PhD.

PANELISTS
Pranam Ben, Founder & CEO, The Garage
Pranam is a successful healthcare, tech entrepreneur. His most recent venture, Visions@work was acquired in 2011 by a publicly traded, global IT corporation NIIT Technologies. He has experience conducting business internationally a result of managing operations in the UK, Japan, India and the UAE. Ben has been featured in CBS Money Watch, Marketwatch, Fast Company, business.com, Silicon India Magazine, Florida Trend, Orlando Business Journal and the Orlando Sentinel, among other media outlets. In 2014, Ben was honored in the inaugural Orlando Business Journal CEO of the Year class, for his leadership, ability to navigate market conditions, and lasting impact in the community. Under Ben’s leadership, The Garage received recognition as one of Orlando Business Journal’s “Best Places to Work” in 2014 for offering an outstanding work environment with great perks.

Robert “Bob” Crutchfield, Partner, Harbert Venture Partners
Mr. Crutchfield joined HMC in September 2008 and serves on the board of Optimal IMX, WellCentive and RegisterPatient. He also serves as the board observer for CliniPace, WiserTogether, MaxCyte and OpenQ. In addition to his responsibilities at Harbert, he serves as the President of the Southeastern Medical Device Association and is a member of the Board of Directors for the Birmingham Venture Club, the Southern Capital Forum and the True Vine Foundation. He is also a member of the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, the Florida High-tech Corridor Council, and serves as the Co-Chairman of the Commercialization Advisory Committee of the Birmingham Business Alliance, on the Steering Committee of the Alabama Obesity Institute at the University of Alabama in Birmingham, and is a Venture Fellow at the University of Alabama in Tuscaloosa and a Visiting Executive in Residence at Auburn University.

Upen Patel, Founder & CEO, AaNeel
Currently, Upen is the President & CEO of AaNeel Infotech, a healthcare software company based in Tampa, Florida – USA and AaNeel Technology Solutions in India. Upen has an illustrious career span working for various health plans, IPAs, and provider groups. He has worked for Wellcare Health plans (NYSE: WCG), was Director of Software Development for the biggest Physicians Group in Central Florida and was the CIO of Citrus Health Care, a United Healthcare (NYSE: UNH) company. Upen has donned many hats as an Executive Sponsor, CIO, Director, Consultant, and Software developer.

Shahid Shah, CEO, Netspective Communications
Shahid Shah is an award-winning Government 2.0, Health IT, and Medical Device Integration software expert and internationally-recognized thought leader with over 25 years of technology strategy, software engineering, entrepreneurship, speaking, and writing experience. He’s a serial entrepreneur that has co-founded and led Netspective.com, Physia.com, InfluentialNetworks.com, HealthcareGuy.com, HITSphere.com, and simplifyMD.com within the last few years; he has another two stealth startups in the works. His primary responsibility is as CEO of Netspective Communications, a computer software architecture & engineering firm delivering custom software for in-house, outsourced, or offshore solutions. Shahid also serves as a senior technology advisor to OMB’s Budget System Branch, the eGov Budget Formulation & Execution Line of Business (BFELOB.gov), Veterans Affairs (VA.gov), OSEHRA.org, and Millennium Challenge Corporation (MCC.gov).
This panel will explore new and innovative partnership models taking place across the country between academic institutions and pharmaceutical companies.

MODERATOR

Dr. Bill Dalton, M2Gen
Dr. Bill Dalton serves as Founder & CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. Before taking this role, he was the President & CEO of Moffitt Cancer Center from 2002 to 2012. He currently serves as the President of the Association of American Cancer Institutes, Chairs the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research, as well as serves on the Institute of Medicine’s National Cancer Policy Forum and various NCI, cancer center and research foundation scientific advisory boards across the U.S. In addition, Dr. Dalton serves at the state level as a member of the Florida Council of 100, an advisory role to the Governor, the Chief Justice, the Legislature, as well as private organizations, to promote the economic growth of Florida and improve the economic well-being and quality of life of the citizens of Florida.

PANELISTS

Bob Reese, Senior VP and Global Partner, Philips Healthcare
Mr. Reese is responsible for leading the Philips HealthTech Transformation Services business, which partners with a global network of providers of healthcare services to offer end-to-end, patient-centric solutions across the continuum of care. Bob works around the world leading solution design and development projects for major public and private healthcare systems. His particular expertise lies in corporate healthcare strategy and in the application of clinical data analytics to improve workflows and outcomes. Bob joined Philips in November 2012 from Computer Sciences Corporation (CSC), where he was partner and managing director of their North American Health Delivery Solutions Group. Prior to this, he was the chief information officer at Memorial Health Care System and held leadership roles at Cap Gemini, Ernst and Young, and Perot Systems.

Manfred Lehnert, VP and Head of Innovation, Takeda Pharmaceutical
Lehnert currently serves as the Vice President and Head of External and Internal Innovation, Oncology Therapeutic Area Unit, Takeda Pharmaceuticals. He has been a Medical oncologist and hematologist for 38 years. This has earned him broad and deep expertise in oncology clinical research and drug development, including precision medicine. He has spent 22 years in academia (Austria, Switzerland, United States, Singapore), 16 years in industry: Eli Lilly, Merck, Millennium/Takeda. His experiences are with translation research, precision medicine, early and late phase clinical drug development; small molecules and biologics; and he has extensive interactions with regulatory agencies (NDAs, sNDAs, BLAs, INDs, MAs; scientific advice procedures) in US, EU, Japan, China, and other countries.

Brett Davis, General Manager of ConvergeHEALTH & Principal, Deloitte Consulting
Brett is the General Manager of ConvergeHEALTH and a principal with Deloitte Consulting. In addition to his role at ConvergeHEALTH, Brett serves on the board of directors of the tranSMART Foundation, and the external advisory boards of both the University of Pennsylvania’s Center for Medical Ethics and Health Policy and the Jefferson School of Population Health. He was also a board member of the Personalized Medicine Coalition for six years. Prior to joining ConvergeHEALTH, Brett was the senior director for global business development and strategy at Oracle Health Sciences, and a business unit executive in IBM’s health care and life sciences business. Brett is a graduate of The Pennsylvania State University.
Collaborative Diagnosis: Patient Genomic Information
12:45 PM – 2:00 PM, Ferman Conference Room
This panel will explore practical issues in precision medicine; including implications for drug development and applied use of molecular tumor board and consult services.

MODERATOR
Dr. Howard McLeod, Moffitt Cancer Center
Dr. Howard McLeod, Pharm.D., is an internationally recognized expert in how genetic makeup affects an individual's response to cancer treatment. He joined Moffitt Cancer Center as the new medical director of the DeBartolo Family Personalized Medicine Institute and senior member in the Department of Cancer Epidemiology. McLeod has been principal investigator for more than $16 million in grants and co-investigator for more than $80 million in grants from the National Institutes of Health. He has also authored more than 450 peer-reviewed papers on pharmacogenomics, applied therapeutics and clinical pharmacology.

PANELISTS
Panna Sharma, President and CEO, Cancer Genetics
Mr. Sharma joined CGI as the company’s Chief Executive Officer in 2010. Prior to joining CGI, Mr. Sharma served as managing partner and founder of TSG Partners, where he established several life science capital market indices that are used today in the life science industry. Mr. Sharma formerly served as Chief Strategy Officer at iXL Enterprises Inc. (“iXL”), was a partner at Interaction Solutions, Inc. and consultant to Putnam Investment Management, LLC as well as the Bank of America Corporation. Mr. Sharma has also served on the board of directors of EpicEdge and as a chairman of the advisory board for EndoChoice.

Teresa Vo, PharmD, Assistant Professor, College of Pharmacy
At USF Health, she is currently working on the development of clinical pharmacogenomics services at Pharmacy Plus, a futuristic community pharmacy practice model owned and operated by the College of Pharmacy. She is an active team member on the Moffitt Cancer Center Personalized Medicine Consult service assessing the actionability of somatic variants to guide therapy. Dr. Vo is also a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC). Her research interests include integrating pharmacogenomics into clinical practice and the electronic health record, health literacy pertaining to pharmacogenomics information, and chemotherapy induced hypertension.

Christine Walko, PharmD, FCCP, BCOP
Clinical & Pharmacogenetics Scientist, Moffitt Cancer Center
Christine M. Walko, Pharm.D., BCOP is experienced in hematology and oncology clinical pharmacology and pharmacokinetics. She was a Clinical Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy, member of the Institute of Pharmacogenomics and Individualized Therapy, clinical pharmacist in the outpatient oncology clinic at the North Carolina Cancer Hospital and Director of the Clinical Pharmacology Laboratory in the North Carolina Cancer Hospital Clinical Trials Unit. She has a track record of pharmacokinetic assay development and analysis in addition to collaborating with numerous investigators on a number of Phase I and correlative pharmacokinetic hematology and oncology trials in both adults and pediatrics. Her research interest centers on utilizing pharmacokinetics and pharmacogenomics to individualize cancer therapy for patients.
Raising Funds: What’s Trending Now
12:45 PM – 2:00 PM, Couch Auditorium

This panel will provide a forum for audience members to hear the experiences of successful bioscience companies

MODERATOR
Julio Esquivez, Partner, SLK Law

Julio C. Esquivel, J.D. is a partner at the law firm of Shumaker, Loop, & Kendrick, LLP. Julio a member of the Firm's Management Committee and has significant experience in corporate, transactional and securities matters, including: public offerings and private placements; domestic and international mergers and acquisitions; recapitalization and restructurings; venture capital; joint ventures; franchising; and Securities Exchange Act reporting obligations. Julio received his Bachelor of Science degree in Finance from the University of Florida in 1988 and his Juris Doctorate from the University of California at Berkeley School of Law (Boalt Hall) in 1991.

PANELISTS

Oscar Bronsther, MD, CEO & CMO, MetaStat, Inc.

Dr. Bronsther, joined the Company as Chief Medical Officer on April 7, 2012 and was appointed CEO on December 21, 2012. Dr. Bronsther is a Diplomat, American Board of Surgery, and since November 2008, has served as the Chairman, Section of General Surgery, at Inova Fairfax Hospital. Since September 2003, he has also served as Clinical Professor of Surgery at George Washington University in Washington, D.C. From 2005 to 2007, he served as Chairman of the Board of National Transplant Network. Dr. Bronsther received his B.A. from the University of Rochester in 1973, his M.D. from Downstate Medical Center in 1978, was a Fellow in Kidney Transplantation at Downstate Medical Center, and was a Fellow in Liver Transplantation at the University of Pittsburgh Center. Dr. Bronsther’s editorial positions include Reviewer, Journal of the American College of Surgeons, Transplantation, Transplant Proceedings, Liver Transplantation and Surgery, and the American Journal of Kidney Disease. Dr. Bronsther is the author of 63 peer-reviewed publications, seven books and book chapters, and has participated in over 30 invited lectures.

Anthony Cataldo, Chairman & CEO, Oxis Biotech, Inc.

Cataldo’s company, Oxis, is focused on the development of immunothereapeutics to treat certain cancers. Most recently, from February 2011 to June 2013 Mr. Cataldo served as Chairman and CEO/ Founder of Lion Biotechnologies, Inc. Mr. Cataldo created Lion/Genesis with the inclusion of assets purchase from the National Cancer Institute (NIH) for their autologous cell therapy technologies developed by Dr. Steven Rosenberg of the NCI for the treatment of Stage Four Melanoma Cancer. Lion has raised in excess of $100,000,000 and has a market value in excess of $500,000,000 from $0.00. In the past, Mr. Cataldo has served as Chairman of the Board of Directors for Brand Partners Group, Executive Chairman of Calypte Biomedical Corporation, CEO & Chairman of the Board of Directors of Miracle Entertainment, and Chairman & CEO of Senetek.

Michael Cerio, Senior VP, Signal Genetics

Mr. Cerio has served as Senior Vice President of Commercial Strategy and Business Development of Signal Genetics (NASDAQ: SGNL) since August 2014. Prior to joining Signal Genetics, Mr. Cerio served as an independent consultant building out commercial plans for oncology diagnostics startups with the life science venture capital firm, MPM Capital. From June 2012 to April 2013, Mr. Cerio served as Consulting Chief Executive Officer for Modulation Therapeutics, a Moffitt Cancer Center spinout that is developing a novel mechanism of action multiple myeloma drug. From April 2012 to April 2013, Mr. Cerio was the President and Chief Executive Officer of Oncolome Diagnostics where he built out commercial plans for oncology diagnostics in myelodysplastic syndrome and non-small cell lung cancer based on inventions from Moffitt Cancer Center. From 2005 through 2011, Mr. Cerio led the licensing, early commercial strategy and merger and acquisition teams at Genzyme Genetics, the clinical diagnostics business unit of Genzyme Corporation. From 1999 through 2005, Mr. Cerio held business development and licensing roles at BG Medicine and Genaissance Pharmaceuticals. Mr. Cerio holds a B.S. in biology from Syracuse University, a M.S. in microbiology from the University of Connecticut and a M.B.A. from Columbia University.

#MoffittBOB
Laszlo Radvanyi, CSO, Lion Biotechnologies

Laszlo Radvanyi is currently Chief Scientific Officer of Lion Biotechnologies developing T-cell therapies for solid tumors, with an established R&D facility at the University of South Florida Innovation Complex (USF Connect) in Tampa, FL. He is also an Adjunct Member Faculty in the Immunology Department at H. Lee Moffitt Cancer Center where he shares a lab and does basic research on NIH-funded projects on tumor immunology. Previously, Dr. Radvanyi was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, M.D. Anderson Cancer Center in Houston from 2005 to 2014. His current work at Lion Biotechnologies focuses on developing current and next generation cell therapies for melanoma and other solid cancers using expanded TIL. He also performs basic and translational research identifying biomarkers in T-cell therapy, improving the anti-tumor function of expanded T cells, and developing improved manufacturing methods for T-cell therapy in collaboration with researchers at Moffitt Cancer Center and other centers.

Raymond Vennare, CEO, CvergenX, Inc.

Raymond F. Vennare is an accomplished business executive and successful entrepreneur with more than two decades of hands-on experience building, growing and launching companies across diverse markets in information technology, biotechnology and life sciences. As founder, investor, senior executive and board director, Raymond’s experience encompasses critical areas of technology commercialization and company formation including capitalization, corporate governance, business development, strategic planning and shareholder relations. Raymond currently serves as Chairman of the Board of Directors and Acting CEO of CvergenX, Inc., a genomic informatics company that, in collaboration with the Moffitt Cancer Center, is developing a technology to provide radiation oncologists the first opportunity to adapt treatment and dose to genetic characteristics of specific tumors and, ultimately, to personalize and optimize radiation treatment planning and therapy. Raymond is also Co-Founder of DiaVacs, Inc., a cell-based immunotherapy company developing a vaccine for Type I Juvenile Diabetes and, Founder of a business practice that counsels clients as diverse as nationally ranked universities and philanthropic organizations to multi-national publicly traded companies.
Avatar DSS

Avatar DSS is developing a Clinical Decision Support System (CDSS) platform that will enable physicians to deliver advanced individualized medicine, by providing them with tools for both better diagnosis and optimal treatment schedules, for a particular disease based on an individual patient’s virtual patient avatar simulation. Avatar DSS is launching their platform first with cancer treatment models developed by the Mathematics/Oncology team at Moffitt.

Healthmyne

HealthMyne, Inc. is a healthcare IT company that brings evidence-based imaging analysis and actionable insights to radiologists and oncologists at the point of care. The company’s unique approach to clinical imaging enables healthcare providers to optimize individual patient care, while lowering overall care cost. The company was founded in 2013 by a seasoned group of highly successful healthcare industry entrepreneurs. For more information, visit healthmyne.com.

Xclerated Learning Dynamics

XLD focuses on improving the performance of individuals in healthcare. Nothing like this exists and at no time has the need for highly engaging learning and performance programs been so crucial to the success of hospitals, Emergency Departments, and physician’s offices. Leveraging a validated competency model XLD is able to personalize a learning program in two ways: First, through role-based learning pathways aligned with specific educational needs. Secondly, through assessments that further personalize the experience by giving the person ONLY the content they need thereby reducing the time and cost associated with training. Highly personal, highly measurable, and highly successful!

Medical Device Investments

MDI was formed last year in Tampa to fill a significant vacuum in the financing and commercialization of promising and highly-marketable medical technologies not met by other funding sources. MDI’s current structure is oriented around Moffitt Cancer Center licensed technologies that relate to the safety of nurses, physicians and patients, ranging from significantly enhancing off-patent devices to developing a revolutionary radiation delivery system for cancer treatment. MDI has also established MDI Engineering that offers design, engineering, prototyping, and consulting services for MDI’s technology portfolio and outside clients.
INVESTOR FORUM
2:30 PM – 4:00 PM, Murphey Conference Room

INVESTOR JUDGES

Robert “Bob” Crutchfield – Harbert Venture Partners
Mr. Crutchfield joined HMC in September 2008 and serves on the board of Optimal IMX, WellCentive and RegisterPatient. He also serves as the board observer for CliniPace, WiserTogether, MaxCyte and OpenQ. In addition to his responsibilities at Harbert, he serves as the President of the Southeastern Medical Device Association and is a member of the Board of Directors for the Birmingham Venture Club, the Southern Capital Forum and the True Vine Foundation. He is also a member of the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, the Florida High-tech Corridor Council, and serves as the Co-Chairman of the Commercialization Advisory Committee of the Birmingham Business Alliance, on the Steering Committee of the Alabama Obesity Institute at the University of Alabama in Birmingham, and is a Venture Fellow at the University of Alabama in Tuscaloosa and a Visiting Executive in Residence at Auburn University.

Matt Rice – Ballast Point Ventures
Prior to joining Ballast Point Ventures, Matt worked in the Strategic Alliances group at the Novartis Institutes for BioMedical Research. He also served as an Analyst in the Health Care Investment Banking Group at Raymond James where he focused primarily on the specialty pharmaceutical, drug distribution and contract research organization sectors. Matt spent two years at Ballast Point Ventures as a Senior Associate prior to attending business school. He graduated from the University of Virginia with a bachelor’s degree in Commerce and from the Harvard Graduate School of Business Administration with an MBA. Matt currently serves on the board of directors at Innocutis, Iconixx, MolecularMD, TissueTech and Y-Prime.

Randy Scott – HealthQuest Capital
Randy’s industry successes include starting Gainesville based NovaMin Technology, Inc. leading it through financing, growth and acquisition by GlaxoSmithKline; a turn-around of USBiomaterials Corp’s bone-grafting business from perennial money-loser to a profitable spin-out and a member of the early management team at LensCrafters as it emerged from start-up to market leader. Today, Randy and his team invest in companies developing medical devices, diagnostics, consumer/OTC health, patient care products, mHealth and Health IT that directly impacts patient treatment or care. Randy is committed to supporting entrepreneurs both in HealthQuest’s portfolio and beyond, including as past chair of the Gainesville Area Innovation Network, board member of the Cade Museum of Invention and Creativity, advisory board member for the Florida Institute for the Commercialization of Public Research and past board member and BioFlorida. Randy graduated from Georgia Tech with a BS in Management Science. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble in Cincinnati.

Henri Termeer – formerly Genzyme
Mr. Termeer was appointed president of Genzyme in 1983 became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, and a member of the Board of Fellows of Harvard Medical School. He sits on the boards of Biotechnology Industry Organization (BIO), Life Sciences Foundation, Boston Ballet, Museum of Science, Project Hope and WGBH. He also serves on the boards of Abiomed, Inc., Allergan, AVEO Pharmaceuticals, Moderna Therapeutics, Verastem, Inc. and Medical Simulation Corporation. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden Business School at the University of Virginia.